Form 4: Castle Biosciences CFO Acquires Restricted Stock Units
SEC Form 4 Filing
Frank Stokes, CFO of Castle Biosciences, acquired 48,744 Restricted Stock Units (RSUs) on March 4, 2024, according to a recent SEC filing.
Summary
- Frank Stokes, the Chief Financial Officer of Castle Biosciences, acquired 48,744 Restricted Stock Units (RSUs) on March 4, 2024.
- Each RSU represents the right to receive one share of Castle Biosciences' Common Stock.
- The RSUs vest in four equal annual installments, starting on March 4, 2025.
- Following the transaction, Mr. Stokes directly owns 48,744 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to stock unit acquisition, which is neutral in sentiment.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's alignment with shareholder interests.
Stakeholder Impact
- The acquisition of RSUs by the CFO aligns his interests with those of the shareholders, as the value of the RSUs is tied to the company's stock performance.
Key Dates
| Date | Description |
|---|---|
| 03/04/2024 | Date of transaction: Frank Stokes acquired 48,744 Restricted Stock Units. |
| 03/04/2025 | Vesting start date: RSUs vest in four equal annual installments beginning on this date. |
| 03/06/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.